NATCO Pharma Secures Landmark Legal Victory; Set to Launch Generic Risdiplam for Spinal Muscular Atrophy (SMA)

NATCO Pharma Ltd. has announced a significant legal and commercial victory following a favorable ruling from the Delhi High Court on October 9, 2025. The court dismissed an appeal by Swiss pharmaceutical major Roche, providing final clearance for NATCO to manufacture and launch its generic version of Risdiplam in India. Risdiplam is a critical, life-saving treatment for Spinal Muscular Atrophy (SMA), a severe, rare genetic disorder that is a leading cause of infant mortality. Strategic & Market Implications: This ruling is a major strategic win, successfully concluding a complex patent litigation. The court's decision, which cited the invalidity of the originator's patent and the overwhelming public interest in making the treatment affordable, underscores NATCO's expertise in navigating intricate intellectual property challenges. By breaking the monopoly on this high-value drug, NATCO unlocks a substantial market opportunity. The originator drug's prohibitive cost has severely limited patient access in India. NATCO plans an immediate launch at a highly competitive Maximum Retail Price (MRP) of ₹15,900, supplemented by patient access programs. This strategy is poised to capture a significant market share and establish NATCO as a key domestic player in the treatment of rare genetic diseases. Investor Outlook: This development positively reinforces NATCO's business model of targeting niche, high-barrier-to-entry specialty generic molecules. The market has reacted favorably to the news, with the company's shares (NSE: NATCOPHARM) closing higher at ₹814.45 on October 9. This successful litigation outcome is expected to contribute meaningfully to revenue growth and strengthen the company's product portfolio and long-term shareholder value.